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ABSTRACT: Cholesterol is a vital component of the human body. It stabilizes cell membranes and is the precursor of bile 
acids, vitamin D and steroid hormones. However, cholesterol accumulation in the bloodstream (hypercholesterolemia) can 
cause atherosclerotic plaques within artery walls, leading to heart attacks and strokes. The efficiency of cholesterol ab-
sorption in the small intestine is of great interest because human and animal studies have linked cholesterol absorption 
with plasma concentration of total and low density lipoprotein cholesterol. Cholesterol absorption is highly regulated and 
influenced by particular compounds in the food supply. Therefore, it is desirable to learn more about natural food compo-
nents that inhibit cholesterol absorption so that food ingredients and dietary supplements can be developed for consum-
ers who wish to manage their plasma cholesterol levels by non-pharmacological means. Food components thus far identi-
fied as inhibitors of cholesterol absorption include phytosterols, soluble fibers, phospholipids, and stearic acid. 
Keywords: cholesterol absorption, functional food, nutraceutical, dietary supplement
INTRODUCTION
Cholesterol is an essential component of the human 
body. Cholesterol functions in a variety of capacities in-
cluding, but not limited to, stabilizing cell membranes 
and serving as precursor for bile acids, vitamin D, and 
steroid hormones. Every cell of the human body can syn-
thesize cholesterol when needed, but cells cannot catab-
olize cholesterol by oxidative processes. Therefore, any 
excess cholesterol must be transported to the liver, se-
creted into bile (as cholesterol or bile acids), and elimi-
nated from the body by the intestinal route. Whole body 
cholesterol metabolism is in a delicate balance. When 
imbalances occur, cholesterol can accumulate in the gall-
bladder promoting gallstone formation. Cholesterol ac-
cumulation in the bloodstream (hypercholesterolemia) 
can cause atherosclerotic plaques to form within artery 
walls. 
The discovery of transporters, receptors, and enzymes 
specific to cholesterol metabolism has changed our un-
derstanding of how sterols are absorbed into the body. 
The transport of cholesterol and phytosterols into the 
enterocyte is a tightly regulated process (Fig. 1). From a 
health standpoint, the efficiency of cholesterol absorp-
tion and the crosstalk with the processes of cholesterol 
and lipoprotein synthesis is of great interest, as many 
studies have linked cholesterol absorption with plasma 
total and low density lipoprotein (LDL) cholesterol con-
centration (1-5). This link is so important that a class of 
drugs was developed that blocks the intestinal absorp-
tion of cholesterol and, consequently, lowers plasma LDL 
cholesterol concentration. This class of drugs has also 
helped researchers elucidate some of the mechanisms of 
cholesterol transport at the cellular level (6,7). One of 
the drugs, ezetimibe, has become an important therapy 
in managing LDL cholesterol levels in individuals who 
can tolerate drug therapy. However, because drugs can 
produce severe side effects, it is desirable to learn more 
about natural food components that inhibit cholesterol 
absorption so that food ingredients and dietary supple-
ments can be developed for consumers who wish to man-
age their plasma cholesterol levels by non-pharmacologi-
cal means. Mc Auley et al. (8) developed a mathematical 
model of whole body cholesterol metabolism and the 
dysfunction that can follow with aging. The authors hy-
pothesized that their model could be used to evaluate 
the effects of lifestyle modifications, such as phytosterol 
and fiber intake, to inhibit cholesterol absorption and ul-
timately the potential for lowering plasma LDL choles-
terol. 
When foods are consumed, cholesterol arrives in the 
small intestine from both the diet and bile (Fig. 1). Die-
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Fig. 1. Transport of cholesterol (CHOL) and phytosterols (PS) in the intestinal lumen, enterocytes, hepatocytes, and plasma. Dietary 
CHOL and PS mix with biliary CHOL from the gallbladder to form micelles within the intestinal lumen. The micelles also contain 
other digested lipids that are transported to the brush border where the lipids are delivered to the enterocyte. Specific transporters, 
scavenger receptor class B type I (SR-BI) and Neiman-Pick C1 Like 1 (NPC1L1), transport the majority of CHOL and PS into the 
enterocyte. However, nearly all of the PS is redirected back to the intestinal lumen by the transporters ATP binding cassette (ABC)
transporter G5 and G8 (ABCG5 and ABCG8, respectively) for excretion from the body. Some CHOL may also be transported back 
into the intestinal lumen by ABCG5 and ABCG8, although evidence for this is less conclusive. About half of the CHOL is packaged 
into lipoproteins and transported into the lymphatic system and eventually the bloodstream for delivery to the liver. Consequently, 
cholesterol absorption efficiency is generally estimated to be about 50∼60%.
tary cholesterol accounts for approximately 300 mg/d (9- 
11), whereas biliary cholesterol is estimated to contrib-
ute 800∼1,400 mg/d (12,13). The liver－not the diet－ 
is therefore the primary source of cholesterol available 
for intestinal absorption, a point that is often underap-
preciated. Consequently, therapies that block cholesterol 
absorption are effective at lowering LDL cholesterol 
mainly because they prevent the reabsorption of endoge-
nous cholesterol back to the liver. This explains why in-
dividuals who consume no animal products (i.e., no cho-
lesterol) will also experience reductions in LDL choles-
terol when given absorption-blocking therapies.
Biliary cholesterol enters the small intestine unesteri-
fied, along with the other major components of bile 
(phosphatidylcholine and bile acids). As the components 
of bile mix with dietary lipids, micelles form spontane-
ously. Micelles are lipid aggregates that form when a 
critical concentration of lipid from bile mixes with lipids 
entering the small intestine from the diet. Bile acids act 
as detergents allowing the lipids to “dissolve” in an aque-
ous environment, facilitating their delivery to the brush 
border. The proportion of bile acids, phospholipid, and 
cholesterol must be maintained within a specific range to 
optimize the formation of micelles in the lumen of the 
intestine (14). 
Furthermore, bile acids are required for the micellar 
solubilization of cholesterol, but are also synthesized 
from cholesterol within the hepatocyte. After micelles 
have facilitated the solubilization, digestion, and absorp-
tion of lipids in the proximal small intestine, bile acids 
are reabsorbed in the distal small intestine (ileum) by 
the apical sodium-dependent bile acid transporter specif-
ic bile acid transporter, ASBT (15). Pharmaceutical com-
pounds known as bile acid sequestrants (cholestyramine 
and colestipol) are effective at lowering plasma LDL cho-
lesterol because they promote intestinal bile acid excre-
tion, which limits their reabsorption, and results in the 
liver using more cholesterol for bile acid synthesis. This 
increased demand for cholesterol in the liver causes an 
upregulation of LDL uptake from the plasma, thus re-
sulting in lower plasma LDL cholesterol concentration. In 
this pathway, micelle formation and cholesterol absorp-
tion is not affected by treatment with bile acid seques-
trants or inhibition of ASBT, because the liver compen-
sates for the reduced bile acid reabsorption by increasing 
the synthesis of bile acids (16,17). This allows the total 
bile acid pool size to remain unchanged, even though the 
turnover of bile acids due to pharmaceutical or dietary 
factors is much greater.
The discovery of intestinal cholesterol transporters has 
been a key component to the continued understanding 
of cholesterol absorption. Transport into enterocytes is 
mediated by a specific transporter, Neiman-Pick C1 Like 
1 (NPC1L1) protein in the proximal small intestine and 
has been shown to be inhibited by the pharmaceutical 
ezetimibe (6). NPC1L1 also transports dietary phytos-
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terols into the enterocyte. Davis et al. (18) first demon-
strated NPC1L1 knockout mice have significantly reduced 
uptake of cholesterol and phytosterols, compared to wild 
type mice. Cholesterol and phytosterols are utilized quite 
differently once taken up into the enterocyte. Despite 
the ability of NPC1L1 to transport both cholesterol and 
phytosterols, less than 1% of dietary phytosterols enter 
the circulation, whereas 50∼60% of intestinal cholester-
ol enters the circulation. This alternate processing of 
phytosterols is due to the ATP binding cassette (ABC) 
transporter G5 and G8 (ABCG5 and ABCG8, respective-
ly) effectively secreting phytosterols back into the lumen 
of the intestine (19-21). Though the role of intestinal 
ABCG5 and ABCG8 in cholesterol transport is not well 
studied, there is some support to the hypothesis that 
upregulating intestinal ABCG5 and ABCG8 transporters 
will divert more cholesterol from the enterocyte back in-
to the intestinal lumen, effectively creating an anti-hy-
perlipidemic effect (22). Yet the potential inability (or di-
minished ability) of cholesterol to interact with ABCG5 
and ABCG8 is one possible explanation for the differenti-
al absorption rates between cholesterol and phytosterols.
Dietary components reduce cholesterol absorption 
through one or more mechanism and a primary mode of 
inhibiting cholesterol absorption is through the binding 
of bile acids and disrupting the formation of micelles. 
When dietary lipids are consumed, all of the components 
of the micelle are transported from the lumen of the in-
testine to the brush border. While absorption of dietary 
triacylglycerol is absorbed very efficiently (90∼100%); 
cholesterol absorption is generally found to be less well 
absorbed at a rate of 50∼60% (23). Although the impact 
on whole body cholesterol balance may be slight, there 
is evidence to support the hypothesis that biliary choles-
terol is absorbed more efficiently than dietary cholester-
ol, due to its association with the bile acids and phos-
pholipid in bile (24).
The following sections of this review focus on specific 
dietary components that inhibit cholesterol absorption 
through known or hypothesized mechanisms. 
PHYTOSTEROLS
Phytosterols are structural components of plant cell 
membranes and function similarly to cholesterol in ani-
mal cells. The most abundant phytosterols are sitosterol, 
campesterol, and stigmasterol, with the structural differ-
ences occurring in the side chain attached to the steroid 
ring. Plant stanols are saturated sterols (i.e., no double 
bond in the steroid ring) and are much less abundant in 
nature compared to their corresponding sterols. In the 
human diet, phytostanols comprise about 5∼10% of the 
total sterol/stanol present (10,25,26). Due to their low 
abundance in the diet, phytostanols are often reported 
as a part of the total “phytosterol” content of a particular 
food or dietary intake. Western societies consume about 
200∼300 mg phytosterols per day (10,25-30), whereas 
Asian and vegetarian diets provide higher amount of 
phytosterols in the diet (31,32).
The cholesterol lowering properties of dietary phytos-
terols have been known for decades. Moderate levels of 
phytosterols consumed in usual diets probably exert 
some minimal effect on cholesterol absorption, although 
higher amounts (1∼3 g/d) are needed to produce signif-
icant reductions in plasma LDL cholesterol. As a thera-
peutic food ingredient, phytosterols/stanols are often es-
terified with long-chain fatty acids to increase their solu-
bility for incorporation into food products. Meta-analyses 
have consistently shown that intake of 1∼3 g/d of phy-
tosterol (or stanol) esters lowers plasma LDL cholesterol 
concentration up to 15% compared to placebo (33-36). 
An inverse dose response relationship exists between 
phytosterol/stanol ester intake and LDL cholesterol con-
centration, but tapers off at intakes above 3 g/d with lit-
tle added benefit at higher intakes (37). 
The mechanisms whereby phytosterols inhibit choles-
terol absorption are not entirely clear and likely includes 
multiple pathways to disrupt cholesterol absorption. Pro-
posed mechanisms include the inhibition of cholesterol 
ester hydrolysis; competition with cholesterol for solubi-
lization into mixed micelles; co-crystallization of choles-
terol and phytosterols; competition for transport across 
the apical membrane of enterocytes; and impaired intra-
cellular re-esterification of cholesterol by acyl-coenzyme 
A:cholesterol acyltransferase-2 (ACAT-2) for incorpora-
tion into chylomicrons and secretion into the lymphatic 
system.
First, the interaction of phytosterol esters with diges-
tive enzymes is a possible point of regulation, although 
the extent of interaction is still uncertain. On one hand, 
Nissinen et al. (38) demonstrated that high levels of si-
tostanol esters infused into healthy subjects were rapidly 
hydrolyzed and incorporated into micelles, causing cho-
lesterol and its esters to accumulate in the oil phase. 
Preferential interaction of phytosterol esters with diges-
tive enzymes would also preclude dietary cholesterol es-
ters from hydrolysis, further limiting cholesterol absorp-
tion. In contrast, it has been suggested that phytosterol 
esters are poorly hydrolyzed by digestive enzymes (39). 
If the phytosterol esters remain intact within the intesti-
nal lumen, they could attract other lipophilic compounds, 
including cholesterol and cholesterol esters, and carry 
them to distal parts of the intestinal where cholesterol 
absorption is much less efficient. Absorption of dietary 
cholesterol esters is dependent upon hydrolysis by pan-
creatic cholesterol esterase (PCE) to yield free cholester-
ol and a free fatty acid. The free cholesterol is then solu-
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bilized by bile to form mixed micelles in the lumen of 
the intestine (40). PCE is responsible for the hydrolysis 
of both cholesterol and phytosterol esters. One study 
has found that both sterol and fatty acid components of 
a sterol ester influence the rate of hydrolysis by PCE, 
with cholesterol esters having the highest rate of hydrol-
ysis by PCE, followed by sitosterol, stigmastanol, and 
stigmasterol esters (41). The authors hypothesized that 
PCE may play a discriminatory role in the hydrolysis of 
sterol esters, specifically phytosterols that can compete 
with cholesterol for incorporation into mixed micelles. 
In a similar study, phytosterol esters fed to hamsters 
were effective at inhibiting cholesterol absorption if the 
phytosterol esters were hydrolyzed and the free sterol 
was allowed to compete with cholesterol for incorpora-
tion into micelles (42). Further research is clearly needed 
to resolve this issue.
Second, as mentioned previously, micelles play a key 
role in lipid absorption, acting as vehicles that transport 
both lipophilic and amphiphilic compounds towards the 
intestinal wall. Cholesterol not dissolved in micelles will 
form a separate oil phase within the intestinal lumen, 
making it generally unavailable for absorption (43). Us-
ing model bile solutions in vitro, Ikeda and coworkers re-
ported that cholesterol solubility was significantly de-
creased in the presence of sitosterol (44-46). They fur-
ther demonstrated that sitosterol, infused with choles-
terol into rat intestinal tracts as an artificial “bile” mix-
ture, significantly reduced cholesterol absorption in vivo 
(45). Armstrong and Carey (40) conducted a thermody-
namic analysis of micellar solubilities and found that si-
tosterol, compared to cholesterol, had a higher binding 
affinity for micelles. In vitro studies in our laboratory sug-
gest that the higher affinity of phytosterols causes choles-
terol to be displaced from the micelle (47). Heinemann 
et al. (48) published an intestinal perfusion study in 
healthy volunteers and found that both sitosterol and si-
tostanol reduced cholesterol absorption by disrupting 
cholesterol solubility in micelles. In another infusion 
study, Nissinen et al. (38) observed that in subjects re-
ceiving either high or low amounts of plant stanol esters, 
cholesterol solubility in micelles was decreased due to 
displacement by plant stanols. Using a variety of in vitro 
techniques, Mel’nikov et al. (49) found the both sitoster-
ol and sitostanol reduced the concentration of cholester-
ol in dietary mixed micelles via a dynamic competition 
mechanism. These investigators further concluded that 
cholesterol, sitosterol and sitostanol compete equally for 
solubilization in micelles. While there is general agree-
ment that phytosterols compete with cholesterol during 
micelle formation, the degree of solubilization likely de-
pends on the composition of other lipids－dietary and 
biliary－present in the intestinal lumen (14).
The third proposed mechanism whereby phytosterols 
reduce cholesterol absorption is co-crystallization of cho-
lesterol with phytosterols. The concept that co-crystal-
lization would render cholesterol unavailable for absorp-
tion has been considered for some time, but the data are 
quite limited. Christiansen et al. (50) investigated the 
solubility and phase behavior of sitosterol and cholester-
ol (and mixtures thereof) in the presence and absence of 
water. As expected, the solubility of both sitosterol and 
cholesterol were significantly reduced in water-acetone 
solutions compared to acetone alone, but the decrease in 
solubility was much greater with sitosterol. When mix-
tures of cholesterol/sitosterol in ratios of 3:1, 1:1, and 1:3 
were co-precipitated from the water-acetone solution, the 
total sterol solubility decreased with increasing propor-
tions of sitosterol, suggesting that the more hydropho-
bic sitosterol promotes co-crystallization with cholester-
ol. Under more realistic conditions, Mel’nikov et al. (51) 
examined the co-crystallization properties of cholesterol 
/sitosterol and cholesterol/sitostanol mixtures from tri-
glyceride oil that was hydrolyzed to mimic the intestinal 
environment during digestion. However, during lipoly-
sis of the model dietary emulsions, no crystal formation 
was detected. The researchers concluded that the solu-
bility of sterols significantly increased in the products of 
lipid hydrolysis and that their solubility increased in par-
allel with solvent polarity (free fatty acids> diglyceride 
oil> triglyceride oil). These results suggest that co-crys-
tallization of phytosterols and cholesterol may not occur 
to a great extent in vivo and would not be a major con-
tributor in reducing cholesterol absorption (51). 
The fourth proposed mechanism involves the regu-
lation of the intestinal transporters NPC1L1, ABCG5, 
and ABCG8. As described earlier, NPC1L1 resides in the 
brush border membrane and transports both cholesterol 
and phytosterols into the enterocyte (6,18,52-54), where-
as ABCG5 and ABCG8 transport phytosterols and possi-
ble cholesterol back to the intestinal lumen (21). In this 
way, phytosterols could compete with cholesterol for 
binding to NPC1L1, although direct evidence for this is 
lacking. It is also possible that phytosterols could inhibit 
gene expression of NPC1L1 (55) or, conversely, enhance 
expression of ABCG5 and ABCG8, which could promote 
cholesterol efflux if, indeed, cholesterol is transported 
by ABCG5 and ABCG8. However, Field et al. (56) re-
cently reported that NPC1L1 mRNA was not changed in 
hamsters fed plant stanols. They also found that ABCG5 
and ABCG8 mRNA was decreased by plant stanols rath-
er than increased, suggesting that the cholesterol low-
ering effect of plant stanols (and sterols) is unrelated to 
changes in gene expression of NPC1L1, ABCG5, or 
ABCG8. The study by Field et al. (56) does not exclude 
the possibility that unknown transporters of cholesterol 
are regulated by phytosterols.
The fifth possible mechanism, in which intestinal 
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ACAT-2 is inhibited by phytosterols, is based on the dif-
ferential affinities of sterols for the enzyme. ACAT iso-
forms have been shown to have significantly lower sub-
strate specificity for phytosterols than for cholesterol 
(57-59), resulting in more unesterified phytosterol being 
available for return to the intestinal lumen (via ABCG5/ 
ABCG8). However, this difference in specificity does not 
appear to be an important mechanism for lowering cho-
lesterol absorption as the presence of sitosterol along 
with cholesterol did not inhibit cholesterol esterification 
(45,57). While the difference in sterol specificity may ac-
count for very low plasma concentration of phytosterols 
in humans, inhibition of ACAT-2 is unlikely a major 
mechanism for reduction in cholesterol absorption.
SOLUBLE FIBERS
Dietary fiber is defined as consisting of nondigestible 
carbohydrates and lignin that are intrinsic and intact in 
plants (60). While dietary fiber is consumed as a part of 
plant material, functional fiber is used as an added in-
gredient in manufactured food products. The Institute of 
Medicine’s Food and Nutrition Board has defined fiber 
accordingly: “dietary fiber” consists of nondigestible car-
bohydrates that are intrinsic and intact in plants, where-
as “functional fiber” consists of isolated nondigestible 
carbohydrates that have beneficial physiological effects 
in humans (61).
Fibers are also categorized by their solubility in water. 
Insoluble fibers are found mainly in cell walls of plants 
and include cellulose, some hemicelluloses and lignin. 
Good sources of insoluble fiber are vegetables, legumes, 
whole wheat (particularly bran), nuts, and seeds. Though 
insoluble fibers have some capacity to hold water, much 
of insoluble fibers impact on the gastrointestinal tract is 
due to added dietary “bulk” that increases both the rate 
of transit through the gastrointestinal tract and fecal vol-
ume. Alternate terms have been suggested by the Insti-
tute of Medicine. It was proposed to use “viscous fiber” 
instead of soluble fiber, and “fermentable fiber” instead 
of insoluble fiber to describe the physiochemical proper-
ties of fiber. Interestingly, previous evidence indicates 
insoluble fibers have little impact on cholesterol concen-
trations (62). More recent evidence shows carrot insolu-
ble fiber consumption results in significant reductions in 
serum triacylglycerol and serum and liver cholesterol, 
while increasing fecal cholesterol and bile acid excretion 
(63). 
In contrast to insoluble fiber adding to fecal bulk, sol-
uble fiber is attracted to water in the intestine and forms 
a viscous matrix that in turn leads to a variety of effects 
on the body. Although soluble fibers are both viscous and 
fermentable, the independent role of viscosity in reduc-
ing cholesterol absorption has been clearly demonstrated 
(4). The consumption of fiber rich foods, specifically sol-
uble fiber, has been associated with improvements in 
diabetes (64), plasma LDL concentrations and coronary 
heart disease (65,66), and gastrointestinal health of pa-
tients with intestinal cancers (67). Much of the evidence 
supporting soluble fibers contribution to improving cor-
onary heart disease is due to their ability to inhibit cho-
lesterol absorption. The hypolipidemic and cardioprotec-
tive effects have been documented feeding trials in ani-
mal (68,69), human (70,71), and systematic reviews and 
meta-analyses (72,73). Furthermore, the U.S. Food and 
Drug Administration has issued statements supporting 
the consumption of dietary fiber in the prevention of both 
cancer and coronary heart disease (74,75).
Soluble fibers can be considered both dietary and func-
tional fibers as they are in native foods and used as addi-
tives in food products. These include pectin, β-glucans, 
fructans, gums, and resistant starch (RS) (i.e., resistant 
to digestion by mammalian enzymes). The pectin family 
has excellent binding and gel-forming properties and has 
been used widely in the food industry as a food additive 
as a thickener, gelling agent, or health supplement. A re-
cent study examining the effect of adding pectin to the 
diet of male Syrian hamsters on high-cholesterol diet 
showed significant reductions in plasma and liver lipids 
(triacylglycerol and cholesterol), and significant increases 
in fecal lipids (cholesterol, triacylglycerol, and bile acids) 
(76). The authors concluded that the soluble dietary fi-
ber included in the diet decreased plasma lipids by re-
ducing lipid absorption in the intestine. 
β-Glucans are found in cereal brans, especially oats 
and barley, and in yeast, the latter being an important 
commercial source (77). β-Glucans provide thickening 
properties when used as a food ingredient. A randomized 
controlled trial was designed to identify the physiologi-
cal effects of concentrated oat β-glucans in humans. The 
trail targeted outcomes related to cardiovascular disease 
risk by measuring serum total cholesterol, LDL-choles-
terol, high density lipoprotein (HDL)-cholesterol, triac-
ylglycerol, apolipoprotein A-1, and apolipoprotein B. Af-
ter the six-week trial was completed, oat β-glucans sig-
nificantly reduced total cholesterol and LDL-cholesterol 
(78). Although fructans are soluble in water, they do not 
have the typical gel-forming or ion- binding properties of 
other soluble fibers (79). Fructans are primarily known 
for their ability to support the growth of beneficial intes-
tinal microflora, rather than contributing to the physical 
characteristics of food products (80).
Gums are consumed as both dietary fiber from leg-
umes, oats, and barley, and as functional fibers. Gums 
consumed as a functional fiber are extracted from seeds, 
seaweed, plant exudates, and microbial fermentation and 
are used for their ability to provide thickening, stability, 
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emulsification, and glossy appearance to food products 
(81). Gums have long been shown to reduce plasma cho-
lesterol in humans (82) and animals (83). More recent 
evidence in rats fed diets enriched with cluster beans for 
eight weeks found significant reductions in serum total 
cholesterol and LDL-cholesterol when compared to the 
respective chow fed controls or high cholesterol diet con-
trols (84). Furthering this point, a confirmatory study 
feeding gum arabic for six months to a Sudanese patient 
population with newly discovered hyperlipidemia found 
significant reductions in total cholesterol, LDL-choles-
terol, and triacylglycerol (85).
RSs are found in a wide variety of plant-based foods 
and are a low calorie, prebiotic dietary fiber. RSs are 
classified into four categories (RS1, RS2, RS3, and RS4) 
based on their physiochemical properties. When added 
as a food ingredient, RSs can impart viscosity to the final 
product. Several types of RS are commercially available 
and may be used as functional fibers to improve intes-
tinal health (86). RS4 is of particular interest, as this RS 
is of the crosslinked type and when added to food, it has 
little impact on the physiochemical and organoleptic 
properties final product. Additionally, RS4 has some 
gastrointestinal side effects such as bloating (87,88). In a 
double blind controlled crossover trail, 86 men and wom-
en were given flour containing RS4. The authors reported 
significant reductions in total cholesterol, non-HDL cho-
lesterol, LDL cholesterol, and HDL cholesterol (89).
The mechanism of action by which dietary fibers pro-
tect against cardiovascular disease has not been fully elu-
cidated. Many hypotheses have been proposed as to how 
dietary fiber reduces the risk of cardiovascular diseases. 
Examples of the potential mechanism of action include 
the interaction with and fermentation of fiber by gut bac-
teria (90,91), delayed gastric emptying (92), increased 
muscle glucose transporter type 4 expression and glucose 
uptake (93), decreased absorption of dietary fats (94), 
and increased excretion of fecal cholesterol (95). Unfor-
tunately, there is some inconsistency in the published 
data regarding the effects of soluble fiber. For example, 
guar gum was reported to decrease cholesterol absorp-
tion in some studies (96,97), but not in others (98,99). 
Similarly, pectin was shown to inhibit cholesterol ab-
sorption in some studies (83,96), while others found no 
effect of pectin on absorption (100,101). The amount of 
soluble fiber consumed, chemical and physical modifica-
tion of the fibers, and the composition of the background 
diet are variables that can affect the research outcomes. 
Despite the variable outcomes reported in the litera-
ture, viscous soluble fibers consistently showed improve-
ments in cardiovascular disease outcomes. Viscous fibers 
were shown to increase the thickness of the unstirred 
water-layer in humans (102,103), as well as reduce the 
amount of cholesterol appearing in the lymph of cannu-
lated rats (46,96). While others have reported increased 
bile acid output in hamsters fed psyllium and suggest 
that increased viscosity of the gastrointestinal contents 
may have disrupted micelle formation and promoted bile 
acid excretion (104,105). While the precise mechanism 
of action of soluble fibers has not been elucidated yet, 
the most prominent mechanism of action is likely due to 
the ability of soluble fibers to form a viscous matrix 
within the gastrointestinal tract that impedes cholesterol 
uptake in the enterocyte.
PHOSPHOLIPIDS
Phospholipids are a group of amphipathic molecules in 
which long acyl chains form a hydrophobic region, while 
a hydrophilic region is formed by a phosphate-contain-
ing “head” group. The acyl chains can be highly variable; 
phospholipids from animals tend to be more saturated 
than those of plant origin. Molecules that comprise the 
polar head group are typically choline, ethanolamine, se-
rine, or inositol, although choline is mostly frequently 
found in both plant and animal phospholipids. Because 
of their unique chemical structure, phospholipids spon-
taneously form lipid bilayers and are therefore the pri-
mary structural components of cell membranes. In addi-
tion to their role in cell membranes, phospholipids are a 
major component of bile and participate in micelle for-
mation and cholesterol solubilization. Phosphotidylcho-
line (PC) is the primary biliary phospholipid and, when 
secreted into the intestine, can exceed dietary phospho-
lipid amounts by as much as 5 to 1 (106). Food sources 
naturally rich in PC include egg yolks, muscle foods, 
peanuts and soybeans. Naturally occurring soybean PC 
contains 10∼20% saturated fatty acids, whereas native 
egg yolk PC contains 40∼50% saturated fatty acids. Food 
manufacturers frequently use purified PC (also called lec-
ithin) as a food ingredient because of its excellent emul-
sifying properties. 
Sphingomyelin (SM) is another phosphoslipid found 
mostly in animal tissues; therefore, good food sources of 
SM include egg yolks, muscle foods, and milk and dairy 
products. SM is similar to PC to the extent they share the 
same phosphate-choline head group and have long chain, 
hydrophobic acyl moieties, but SM differs in several ways 
from naturally occurring PC. Whereas the backbone of 
PC is a glycerol base, the backbone of SM is a sphingoid 
base, which increases the polarity of SM and allows for 
stronger intra- and inter-molecular hydrogen bonding 
(107). The main acyl chain of SM is usually longer than 
the fatty acyl chains of PC and is frequently saturated. 
These characteristics contribute to a stronger interaction 
between cholesterol and SM in cell membranes compared 
to other phospholipids (108,109).
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The ability of PC to inhibit cholesterol absorption was 
first demonstrated in experimental animals (110,111) 
and later in humans given intraduodenal PC infusion 
(112). Kesaniemi and Grundy (113) also found a small 
but significant reduction in cholesterol absorption in hy-
perlipidemic patients fed soy PC. Koo and colleagues 
(114,115) have shown that egg PC inhibits cholesterol 
absorption in lymph duct cannulated rats, and that egg 
PC is more effective at reducing absorption than soy PC. 
In fact, soy PC did not interfere with cholesterol absorp-
tion but rather produced a slight increase in absorption 
relative to no-PC controls. These researchers suggested 
that the higher degree of fatty acid saturation in egg PC 
compared to soy PC may have caused greater disruption 
of micellar solubilization of cholesterol. This hypothesis 
was further supported in rats that had lower rates of 
cholesterol absorption when fed hydrogenated (i.e., fully 
saturated) PC compared to native PC, whether from soy 
(116) or egg (115). 
SM also inhibits cholesterol absorption in experimental 
animals, and this effect has been shown to be dose-de-
pendent (106,116,117). Noh and Koo (118) further re-
ported that milk SM was a more potent inhibitor than 
egg SM, suggesting that a higher degree of saturated and 
long chain length of milk SM may be important factors. 
Eckhardt et al. (106) indicated that milk SM compared 
to egg PC was more effective in reducing cholesterol sol-
ubility in micelles and in limiting cholesterol uptake in 
Caco-2 cells. They also observed that milk SM signifi-
cantly reduced cholesterol absorption in mice, whereas 
egg PC had no effect. On an equal molar basis, it appears 
that SM is a more effective inhibitor of cholesterol ab-
sorption than PC. Despite considerably more dietary and 
biliary PC compared to SM in the intestine under normal 
conditions, the addition of SM to the diets of experimen-
tal animals was still able to reduce cholesterol absorption 
in the presence of endogenous PC, indicating a higher 
potency of SM relative to PC (106,116). Feeding mice 
SM (119) or a mixture of sphingolipids (120) resulted in 
lower cholesterol absorption and an added benefit of pro-
tecting against liver steatosis (non- alcoholic fatty liver 
disease). Human studies, however, are limited and the 
efficacy of dietary SM is still uncertain (121,122). 
There appears to be multiple mechanisms by which di-
etary phospholipids inhibit cholesterol absorption. In vi-
tro studies have suggested that intact (undigested) PC 
disrupts micelle formation by interfering with enzymatic 
hydrolysis of dietary lipids. Studies have indicated that 
the presence of PC on the surface of lipid emulsions hin-
ders the hydrolysis of triglycerides (123,124), which also 
inhibits cholesterol uptake into IEC-6 intestinal cells 
(125). The addition of phospholipase A2 in vitro was able 
to overcome the inhibitory action of PC, resulting in in-
creased absorption of cholesterol into Caco-2 cells (126). 
Because PC is rapidly hydrolyzed by digestive enzymes 
under normal conditions, relatively large amounts of di-
etary PC are likely needed to inhibit cholesterol absorp-
tion. By comparison, dietary SM is digested slowly and 
may affect cholesterol in two ways. First, SM binding to 
cholesterol in the intestinal lumen may prevent choles-
terol from incorporating into micelles. The preferential 
affinity of cholesterol for SM is well-documented (127- 
129), and lack of micellarization results in increased fe-
cal cholesterol excretion. Second, the strong association 
between cholesterol and SM in the enterocyte mem-
brane may prevent cholesterol from interacting with its 
key transport protein, NPC1L1, as reported in intestinal 
cell lines (130) and animal studies (131).
STEARIC ACID
Stearic acid is an 18-carbon saturated fatty acid present 
in virtually all edible fats and oils, primarily as a con-
stituent of triacylglycerol molecules. Common fats/oils 
in Western diets having the highest percentage of stearic 
acid are beef fat (20%) and cocoa butter (33%). Several 
tree nuts and seeds indigenous to West Africa, India, 
and Southeast Asia contain relatively high percentages 
of stearic acid, including dhupa, illipe, kokum, mango 
kernel, sal, and shea (132). The use of sheanut oil (shea 
butter) and sal oil has expanded into Europe and Japan 
as cocoa butter substitutes in chocolate making. These 
stearic acid-rich oils are also used in cosmetics, candles, 
and other industrial products worldwide. Sheanut oil 
contains about 38% stearic acid and sal oil contains 
about 34% stearic acid. 
It is generally accepted worldwide that consumption of 
saturated fatty acids (SFA) raises LDL cholesterol con-
centration and increases the risk of atherosclerotic di-
seases. The World Health Organization, the European 
Food Safety Authority, the Dietary Guidelines for Amer-
icans, and many other organizations recommend limit-
ing intake of SFA. However, stearic acid is unique among 
dietary SFA because it does not raise plasma cholesterol 
levels, as originally observed in the 1960s by Keys et al. 
(133) and Hegsted et al. (134). When replacing trans fat-
ty acids or other saturated fatty acids in the diet, stearic 
acid lowers LDL cholesterol (135). The neutral or cho-
lesterol lowering effect of dietary stearic acid has been 
observed repeatedly in animal and human studies (135- 
137). Despite these observations, the American Heart 
Association acknowledges that there is no simple way to 
incorporate specific information about stearic acid into 
dietary guidelines because stearic acid is generally found 
with other saturated fatty acids in foods and because the 
content of specific fatty acids is not provided to consum-
ers (138).
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Animal studies have demonstrated that the cholester-
ol-lowering effect of stearic acid is mediated by reducing 
cholesterol absorption. Feldman et al. (139,140) were the 
first to demonstrate a reduction in cholesterol absorption 
using three different methods to quantify cholesterol ab-
sorption (i.e., plasma isotope ratio method, fecal dual iso-
tope method, and lymph duct cannulation), and in each 
case absorption was significantly decreased by stearic 
acid. Other studies using lymph duct cannulated rats fed 
stearic acid-enriched diets showed significant reductions 
in cholesterol absorption (141,142). Schneider et al. (143) 
used a more realistic dietary approach by feeding ham-
sters the NIH-07 cereal-based diet specifically enriched 
in single fatty acids (stearic, palmitic, oleic, linoleic, or 
trans fatty acids); cholesterol absorption was significant-
ly reduced in hamsters fed stearic acid compared to the 
other fatty acids. As a result of lower cholesterol absorp-
tion, fecal cholesterol excretion was increased in rats and 
hamsters fed stearic acid diets (143-145).
Schmidt and Gallaher (146) reported that cholesterol 
solubilization was decreased within the intestinal con-
tents of rats fed stearic acid-enriched diets. One possible 
mechanism of action of stearic acid is its ability to inter-
fere with micelle formation through its incorporation in-
to phospholipids. Unlike most of the other food compo-
nents that inhibit cholesterol absorption, stearic acid is 
relatively well absorbed into the bloodstream and body 
tissues. Wang and Koo (147,148) reported that, after ab-
sorption, stearic acid was preferentially incorporated in-
to hepatic and biliary phospholipids compared to other 
dietary fatty acids. Cohen and Carey (149) demonstrated 
that micelle stability and cholesterol solubility were im-
paired when micellar phospholipids contained stearic ac-
id compared to unsaturated fatty acids. Another possible 
mode of action may involve alterations in the bile acid 
species present in the enterohepatic circulation. We have 
shown that dietary stearic acid decreased the proportion 
of secondary bile acids in the gallbladder compared to 
primary bile acids, thus decreasing the overall hydropho-
bicity index (150). Similarly, Hassel et al. (151) reported 
significantly lower proportions of secondary bile acids in 
feces of hamsters fed stearic acid. Secondary bile acids 
are more hydrophobic than primary bile acids and their 
diminished presence in the enterohepatic circulation can 
decrease the efficiency by which micelles solubilize cho-
lesterol (40). It is also possible the stearic acid exerts 
some regulatory effect on cholesterol transport into (or 
within) the enterocyte, although this has not been re-
ported. Nevertheless, dietary stearic acid most likely in-
hibits cholesterol absorption through systemic mecha-
nisms rather than disrupting micelle formation through 
physical interactions within the intestinal lumen.
OTHER CHOLESTEROL-LOWERING FOOD 
COMPOUNDS
Several other compounds in the food supply have been 
identified as having cholesterol-lowering properties. Their 
mechanisms of action are poorly understood and may not 
be directly involve reduced cholesterol absorption. Nev-
ertheless, we felt these compounds should be mentioned 
in this review. 
Alkylresorcinols
Wheat alkylresorcinols were recently found to increase 
cholesterol excretion by 39.6% and decrease blood cho-
lesterol concentration by 30.4% in mice fed a high fat and 
high sucrose diet designed to induce obesity and glucose 
intolerance (152). The same group completed a follow- 
up to that study with the aim of identifying the possible 
mechanism of action wheat alkylresorcinols have on in-
creasing fecal cholesterol excretion. The follow-up study 
confirmed wheat alkylresorcinols effects on increasing 
cholesterol excretion and in vitro studies revealed a dose 
dependent decrease in micellar cholesterol solubility in 
model bile (153).
Policosanols
Consuming policosanols was a promising therapy for 
dyslipidemia. An early clinical trial examining the effi-
cacy and tolerability of 10 mg/d policosanol in elderly 
patients (154) and a follow up clinical trial by the same 
group in patients with non-insulin-dependent diabetes 
mellitus and elevated serum total and LDL cholesterol 
(155) found serum total cholesterol was reduced by 16.4 
and 17.5%, respectively, and serum LDL cholesterol was 
reduced by 17.5 and 21.8%, respectively. Since these ear-
ly studies, there has been limited evidence to support pol-
icosanols effectiveness in treating dyslipidemia and trials 
delivering twice the dose (20 mg/d) found no effect on 
reducing serum cholesterol concentration (156).
Guggulsterone
Guggulsterone (also known as guggul) has been used in 
Ayurvedic medicine and is classified as a plant steroid. A 
variety of in vitro and in vivo studies has been performed 
using guggul with consistent mechanistic and clinical re-
sults. A recent clinical trial registered with the Clinical 
Trial Registry of India found consumption of fresh gug-
gul found significant reductions in serum total choles-
terol, triglyceride and very LDL cholesterol (157). The 
mechanism of action for guggul’s lipid lowering efficacy 
has largely been isolated to agonistic effects on the far-
nesoid X receptor (FXR). Wild type and FXR null mice 
were fed a high cholesterol diet supplemented with gug-
gul, while the wild type mice saw significantly lower ac-
cumulation of hepatic cholesterol; the FXR null mice re-
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alized no effect of guggul consumption (158). This led 
the investigators to hypothesize that the mechanism of 
action is the agonistic behavior of guggul on FXR.
Cyclodextrins
Cyclodextrins are reported to have beneficial effects on a 
variety of health outcome measures from body weight 
control to allergy suppression. A recent mechanistic study 
examining the effects of α-cyclodextrin on micelle forma-
tion in fed-state simulated intestinal fluid found precip-
itation of cyclodextrin bound lecithin (159). The results 
suggest that α-cyclodextrin disrupts cholesterol absorp-
tion by precipitating lecithin from bile salt micelles with-
in the intestinal lumen. Mice fed a high cholesterol diet 
treated with β-cyclodextrin exhibited a reduction in ath-
erosclerotic plaque size and cholesterol crystal deposi-
tion in the sub-endothelial space, which promoted pla-
que regression (160). Further study is needed to deter-
mine the efficacy of cyclodextrin in managing atheroscle-
rosis in humans. 
Probiotics
Probiotics are microorganisms that, when consumed, 
promote a beneficial health effect such as Bifidobacterium 
animalis and Lactobacillus acidophilus. A meta-analysis of 
randomized controlled trials examining the effects of 
probiotics on their lipid lowering effects published be-
tween 2000 and 2014 included 15 studies and 788 total 
subjects (161). The meta-analysis revealed significant 
reductions in serum total and LDL cholesterol when 
consuming probiotics as fermented milk or yogurt when 
compared to consuming probiotics in a capsule. The 
mechanism for these effects can be attributed, at least 
partially, to the decrease in intestinal cholesterol absorp-
tion through the co-precipitation of cholesterol with de-
conjugated bile salts, intestinal conversion of cholesterol 
to coprostanol, and the inhibition of the expression of 
the intestinal sterol transporter NPC1L1 (162).
Saponins
Saponins are found mainly in plants but are also present 
in lower marine animals and some bacteria. Saponins 
possess a wide range of biological activities and some 
are known to be toxic. However, the human diet contains 
appreciable amounts of saponins, particularly in legumes 
and alfalfa sprouts. Dietary saponins are poorly absorbed, 
thus suggesting their cholesterol-lowering action occurs 
in the intestine. One possible mechanism of action is the 
ability of saponins to form insoluble complexes with cho-
lesterol in the intestinal lumen (163,164). Another pos-
sibility is direct binding of saponins to bile acids, which 
would disrupt micelle formation and, consequently, cho-
lesterol absorption. However, Harwood et al. (165) re-
ported no change in bile acid absorption or interruption 
of the enterohepatic circulation of bile acids in hamsters 
fed saponins, despite significant reduction in cholesterol 
absorption.
CONCLUSION
Many cholesterol-lowering compounds are naturally pres-
ent in the human food supply. Each of these compounds 
can be isolated, purified, and subsequently used as addi-
tives in food products and dietary supplements designed 
specifically for reducing plasma LDL cholesterol concen-
tration. This review focused on compounds that lower 
plasma cholesterol by inhibiting cholesterol absorption 
in the small intestine, including phytosterols, soluble fi-
bers, phospholipids, and stearic acid. All of these com-
pounds appear to exert their effects by interfering with 
micellar solubilization of cholesterol within the intesti-
nal lumen. This can be the result of displacing cholester-
ol from the micelle, binding or precipitating cholesterol, 
impeding the movement of cholesterol by forming a vis-
cous matrix, inhibiting digestive enzymes, binding bile 
acids, and decreasing their participation in micelle for-
mation, or downregulating cholesterol transporters with-
in the enterocyte. Stearic acid also appears to work sys-
temically by incorporating into hepatic and biliary phos-
pholipids, which destabilizes micelles and reduces cho-
lesterol solubility. These compounds are attractive to 
food and nutraceutical companies because, in most cases, 
they are regulated as foods and not drugs. Most of the 
compounds work entirely within the intestine and are 
poorly absorbed, if at all, thus significantly reducing (or 
eliminating) the risk of toxicity. Some also contribute 
important functional properties when added to foods, 
such as emulsification, improved texture, calorie reduc-
tion, and in the case of soluble fibers, provide prebiotic 
action. In view of these desirable characteristics, manu-
facturers are likely to develop a greater diversity of food 
and nutraceutical products in the coming years giving 
consumers more choices to manage their plasma choles-
terol levels through nonpharmacological means. 
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